Literature DB >> 35210186

Common bacteria and treatment options for the acute and chronic infection of the total ankle arthroplasty.

Kathrin Pfahl1, Anke Röser2, Oliver Gottschalk3, Hubert Hörterer3, Alexander Mehlhorn2, Patrick A Dolp2, Markus Walther2.   

Abstract

BACKGROUND: There is little valid data available on managing infected total ankle arthroplasty (TAA).
METHODS: A single-center, retrospective evaluation from 20 patients with PJI (periprosthetic joint infection) of the ankle compared the bacteria isolated by preoperative arthrocentesis and intraoperative cultures to the pathogens of knee PJI. Long-term failure rates of irrigation and debridement (I&D) and polyethylene exchange, revision arthroplasty, and arthrodesis were analyzed.
RESULTS: The most common bacteria were Staphylococcus aureus and Coagulase-negative staphylococci. There was no significant difference when comparing the causing pathogens of PJI of the ankle with the knee. After a follow-up of 50,4 months, the long-term failure rate after I&D and polyethylene exchange was 40%, and of revision was 9%.
CONCLUSIONS: We concluded that the pathogenesis of PJI of the ankle and knee seems to be comparable. Regarding treatment options, we found that standardized techniques for PJIs of the knee have their limitations regarding infected TAA.
Copyright © 2022 European Foot and Ankle Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bacteria; Infected ankle replacement; Revision; Total ankle arthroplasty; Treatment

Mesh:

Substances:

Year:  2022        PMID: 35210186     DOI: 10.1016/j.fas.2022.02.010

Source DB:  PubMed          Journal:  Foot Ankle Surg        ISSN: 1268-7731            Impact factor:   2.840


  1 in total

1.  Correlation between EFAS- and MOCART score and clinical outcome after AMIC®-procedure for osteochondral lesion of the talus.

Authors:  Oliver Gottschalk; Judith Mazet; Florian Kerschl; Hedwig Schenk; Eduardo M Suero; Hubert Hörterer; Wolfgang Böcker; Markus Walther
Journal:  Arch Orthop Trauma Surg       Date:  2022-05-21       Impact factor: 3.067

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.